Assessment of the efficacy and safety of the lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer in the real clinical practice.

  • The proportion of radioiodine-refractory differential thyroid cancer (RR DTC) among DTC reaches 5%, these patients are widely used multikinase inhibitors, in particular lenvatinib.

    Methods. There were studied 17 patients with RR DTC, receiving lenvatinib in the period from Dec 2016 to the present time. To assess the effectiveness and safety of each patient is filled Case Report Form (the age of the patient, the scope of surgical treatment, classification TNM, histological version, the total entered activity I-131, preceded target therapy, the level of tumor markers before treatment and change it in the process, ECOG, the date of initiation of lenvatinib, the initial dose of the drug and It’s change, adverse events (AE), the effectiveness of therapy, the duration of therapy, data of osteoscintigraphy, ultrasound, CT or PET – CT.

    Results. Median age of patients is 43 years (32-80), the status of ECOG 0-1 (82%). Partial response (PR) received in 41% of patients, stabilization in 35% of patients, the progression in 2% and  22% of patients are not rated. Currently, therapy continues for 76% of patients, so the progression free survival is not evaluated. AE were: arterial hypertension – 59%, astenia – 35%, reduction of body weight-70,5%, proteinuria-23,5%. Reduction of dose required for 29,4% of patients, stop of the drug treatment (due to AE) – 4%.

    Conclusions. Lenvatinib has demonstrated the effectiveness and AE profile of patients with RR DTC in real clinical practice in our clinic common with data in earlier known clinical trials.


Leave a Reply